10104367Development of novel, next-generation platform technology for in-vivo generation of CAR T-cells for Autoimmune disordersClosedCollaborative R&DInnovate UKChimeris is developing SENDeR (Specific Engager Nanoparticle Delivery Reagents), a pioneering, patented, nanoparticle platform for Chimeric Antigen Receptor (CAR) T-cell therapies with high specificity and efficacy. This project focuses on the in vivo validation of applying SENDeR to target B cell elimination to realise drug-free remission in people with the chronic autoimmune condition, systemic lupus erythematosus.